MK-677 and Ibutamoren: Human Trials, Functional Outcomes and Risks
Published · Page updated
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
MK-677, also called ibutamoren, is a nonpeptide growth-hormone secretagogue. It has been studied in people, making the important question more specific than whether research exists: did a hormone response translate into a meaningful clinical benefit, in whom, and with what harms? Original ibutamoren study identifying the compound
At a glance:
MK-677 is not a peptide; raising growth hormone does not change its chemical class.
Hormone levels, body composition and physical function are different outcomes.
A hip-fracture trial stopped early after a heart-failure safety signal.
Ongoing pediatric research is distinct from FDA approval or evidence for general anti-aging use.
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells research materials. This commercially interested, AI-assisted summary is not an independent scientific review. Selected sources were checked November 11, 2026; access limits appear below.

What does MK-677 do in the studies?
The original clinical literature describes ibutamoren mesylate as a nonpeptide compound that stimulates growth-hormone release. A 2001 study in 18 prepubertal children with growth-hormone deficiency measured short-term GH, IGF-I and related hormone responses. It did not establish final adult height or a general benefit in healthy adults. Codner and colleagues, original abstract
A secretagogue stimulates release of another substance. That makes administered ibutamoren, the body's growth hormone and downstream IGF-I different parts of the research question. They should not be described as the same intervention. The clinical papers also identify a chemical form and formulation; those details cannot be assumed from a research-product name alone.
The distinction between a hormonal endpoint and an outcome a person experiences runs through this evidence. A blood result can show biological activity while leaving strength, independence or cognition unchanged. Our CJC-1295 and ipamorelin evidence guide discusses the same endpoint problem for different compounds, without implying equivalence.
Did more fat-free mass mean better function?
Nass and colleagues studied 65 healthy adults aged 60–81 in a randomized, blinded, placebo-controlled trial. The principal one-year assessment found increased GH and IGF-I and a mean fat-free-mass increase of 1.1 kg with MK-677, compared with a 0.5 kg decrease with placebo. Strength and function did not improve. The investigators also acknowledged limited statistical power for functional endpoints. Nass and colleagues, 2008
Abdominal visceral fat and total fat mass did not differ significantly between groups. Blood glucose increased and insulin sensitivity decreased; appetite, mild transient lower-leg swelling and muscle pain were reported. These findings should accompany the body-composition result rather than disappear behind a “lean mass” headline. Original trial abstract
Human study | Population and design | Finding that limits a simple benefit claim |
|---|---|---|
65 healthy older adults; randomized placebo comparison | More fat-free mass, without demonstrated strength or function improvement | |
123 older hip-fracture patients; randomized placebo comparison | Most functional measures did not improve; early termination for a safety signal | |
563 patients with mild-to-moderate Alzheimer's disease; randomized placebo comparison | IGF-I rose, but clinical progression measures did not improve |
“Fat-free mass” and “functional muscle gain” are not interchangeable conclusions. The former describes a body-composition measurement; the latter requires suitable performance testing. A trial may also be too small to settle a functional question conclusively. That uncertainty does not turn an unproven benefit into a positive finding.
What happened in the hip-fracture and cognition trials?
The hip-fracture study assigned 62 patients to MK-0677 and 61 to placebo. IGF-I increased and one gait-speed comparison favored the compound, but stair-climbing power and several other functional measures did not show improvement. The trial ended early because of a congestive-heart-failure safety signal. The authors judged the safety profile unfavorable in this population. Adunsky and colleagues, original abstract
The result should neither be hidden nor generalized into a precise heart-failure rate for every other population. Early stopping, patient vulnerability and the limited accessible reporting matter. The observed gait finding also should not be expanded into a claim of broadly improved rehabilitation.
In the Alzheimer's study, 563 participants were randomized and 416 completed treatment and assessments at 12 months. Serum IGF-I increased, but the groups did not differ significantly on the selected cognitive, daily-function and global clinical measures. The intervention did not slow progression under the studied conditions. Sevigny and colleagues, original abstract
Together, these trials illustrate a concrete limitation of surrogate endpoints: successfully changing a proposed biological pathway can coexist with failure to improve the clinical outcome. They concern defined patient groups, not a direct test of athletic performance or longevity.
What is the current FDA and research context?
FDA's public safety notice identifies ibutamoren as an ingredient that is not FDA approved. It describes concerns including fluid retention, glucose metabolism and insulin sensitivity, and potential congestive heart failure in certain individuals. This current source check is distinct from interpreting a historical trial. FDA safety notice, rechecked November 18, 2026
Clinical development nevertheless continues. The ClinicalTrials.gov record for NCT06948214, rechecked November 19, 2026, lists a recruiting phase 3 LUM-201 study in children with growth-hormone deficiency. The record was last updated October 19, 2026, but its recruitment status was last verified in May 2026 and may lag actual activity. Its primary outcome is annualized height velocity after 12 months; enrollment is estimated at 150. This is a registered plan and status report, not a completed efficacy result. Official trial record
A pediatric deficiency study cannot establish benefits for healthy adults, and trial registration does not confer approval. The record also does not authenticate the composition or quality of material sold elsewhere under MK-677 or ibutamoren names.
Common questions about MK-677 research
Is MK-677 a peptide?
No. The original clinical literature identifies ibutamoren as a nonpeptide growth-hormone secretagogue. Stimulating release of a peptide hormone does not make the stimulating compound a peptide. Original identity record
Does increased fat-free mass establish better strength?
No. The selected older-adult trial reported increased fat-free mass without demonstrated strength or function improvement; its statistical power for functional outcomes was limited. Original trial abstract
Is MK-677 established as safe for general anti-aging use?
The selected trials and FDA notice do not establish that conclusion. Their populations, follow-up and reported harms must remain visible. A hormonal response or a registered pediatric study cannot supply missing evidence for another intended use. FDA safety notice
To assess a new claim, identify the exact material, population, comparator, duration and measured outcome. Keep adverse events, statistically nonsignificant findings and missing follow-up beside favorable observations. Our study-reading guide and growth-hormone research hub provide the broader framework.
Source-access scope, November 11, 2026: Original abstracts for the four clinical reports, FDA's public notice and the current trial-registry record were checked. Full clinical papers and participant-level datasets were not reviewed in this pass. This selected-source summary is not a systematic review, a prescribing guide or an assessment of any current stock lot. Catalog materials are for lawful laboratory research, not human or veterinary use.
The November 18 presentation update rechecked the Codner and Nass indexed abstracts, FDA notice and official trial record. The other clinical summaries retain their November 11 access scope; the clinical full texts were not re-reviewed.
References
Nass and colleagues, body-composition and functional outcomes in older adults, indexed abstract
Adunsky and colleagues, hip-fracture recovery trial, indexed abstract
Sevigny and colleagues, Alzheimer's disease trial, indexed abstract
On November 19, 2026, we rechecked the four indexed study abstracts, FDA notice and registry record. Full clinical papers and underlying datasets were not reviewed; registry entries can lag actual trial activity.
